Overview
- 9 inspections across 9 sites are on record.
- 1 Form 483 observation is attributed to this investigator.
- Most recent recorded activity is 2023-08-04.
At a glance
Inspections
9
Sites
9
Observations
1
Career since
Oct 2018
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| ROSLIN CELL THERAPIES LIMITED | 4 Aug 2023 | Biologics | On file |
| Biomay Ag | 27 Jul 2023 | Biologics | On file |
| Polymun Scientific Immunbiologische Forschung GmbH | 20 Jul 2023 | Biologics | |
| GC Biopharma Corp_Ochang Plant | 28 Apr 2023 | Biologics | On file |
| Biogen U.S. Corporation | 9 Dec 2022 | Biologics | On file |
Sites inspected
ROSLIN CELL THERAPIES LIMITEDEdinburgh, United Kingdom1 insp.
Biomay AgVienna, Austria1 insp.
Polymun Scientific Immunbiologische Forschung GmbHKlosterneuburg, Austria1 insp.
GC Biopharma Corp_Ochang PlantCheongju, Korea (the Republic of)1 insp.
Biogen U.S. CorporationDurham, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Carl A Perez3 shared
Elena L Gubina2 shared
Jessica Chery1 shared
Xiuju Lu1 shared
Zhaohui Ye1 shared
Malgorzata G Norton1 shared
Roger F Zabinski1 shared
Alifiya H Ghadiali1 shared
Tiffany M Lucas1 shared
Hoda N Abadeer1 shared
Full investigator report
Get the verbatim findings behind Gregory A Price's 1 observation
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site